Clinical Trial Update: Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia [Phase 2]

View source ↗

Summary

Phase 2 study evaluating pirtobrutinib in combination with venetoclax for Waldenström macroglobulinemia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Pirtobrutinib (pirtobrutinib)
• Venetoclax (venetoclax)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Waldenstrom Macroglobulinemia | Phase 2 | Status: RECRUITING